ArticlePDF Available

Abstract

HIV stigma remains a significant barrier to effective prevention, treatment, and care efforts worldwide. Despite advancements in medical science and increased awareness, the persistence of stigma continues to hinder progress in combating the HIV/AIDS epidemic. This review explores the transformative potential of collective efforts in addressing HIV stigma. By fostering unity among individuals, communities, and organizations, collective action can challenge stigma, promote acceptance, and improve the lives of those affected by HIV. Through a comprehensive examination of existing research, interventions, and advocacy initiatives, this article highlights the importance of solidarity in confronting HIV stigma and advancing public health goals.
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
The Power of Unity: Collective Efforts in Confronting HIV Stigma
*Emmanuel Ifeanyi Obeagu1 and Getrude Uzoma Obeagu2
1Department of Medical Laboratory Science, Kampala International University, Uganda
3School of Nursing Science, Kampala International University, Uganda
*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science,
Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-
4538-0161
Abstract
HIV stigma remains a significant barrier to effective prevention, treatment, and care efforts
worldwide. Despite advancements in medical science and increased awareness, the persistence of
stigma continues to hinder progress in combating the HIV/AIDS epidemic. This review explores
the transformative potential of collective efforts in addressing HIV stigma. By fostering unity
among individuals, communities, and organizations, collective action can challenge stigma,
promote acceptance, and improve the lives of those affected by HIV. Through a comprehensive
examination of existing research, interventions, and advocacy initiatives, this article highlights the
importance of solidarity in confronting HIV stigma and advancing public health goals.
Keywords: HIV, Stigma, Collective Efforts, Unity, Awareness, Advocacy, Community Support,
Public Health
Introduction
The global HIV/AIDS epidemic has not only posed significant challenges in terms of public health
but has also exposed deep-rooted social prejudices and stigma. Despite advancements in medical
science, HIV stigma persists as a formidable barrier to effective prevention, treatment, and care
efforts. This enduring stigma is often fueled by misconceptions, fear, and discrimination, creating
a hostile environment for individuals living with or affected by HIV/AIDS. As such, addressing
HIV stigma has become a critical priority in the global fight against the epidemic. The impact of
HIV stigma extends far beyond individual experiences, affecting entire communities and societies.
Stigma not only exacerbates the psychological and emotional burden of living with HIV but also
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
hampers efforts to prevent new infections and provide adequate care and support. It drives
individuals underground, discouraging them from seeking testing, treatment, and support services,
thereby perpetuating the spread of the virus. Moreover, HIV stigma intersects with other forms of
discrimination, including those based on gender, sexuality, race, and socioeconomic status, further
marginalizing vulnerable populations.1-24
Recognizing the complex and multifaceted nature of HIV stigma, there has been a growing
emphasis on the power of collective efforts in confronting this pervasive issue. Collective action
brings together diverse stakeholders, including people living with HIV, healthcare professionals,
policymakers, activists, and community members, to challenge stigma and drive positive change.
By fostering unity and solidarity, collective efforts empower individuals and communities to
advocate for their rights, access resources, and challenge discriminatory practices. Over the years,
grassroots movements, advocacy campaigns, and community-based organizations have played a
crucial role in challenging HIV stigma and promoting social inclusion. These initiatives provide
platforms for education, dialogue, and activism, raising awareness about HIV/AIDS and
challenging stereotypes and misconceptions. By amplifying the voices of those affected by HIV,
these collective efforts have helped break down barriers, promote empathy, and foster a supportive
environment for individuals living with HIV/AIDS.25-39
Understanding HIV Stigma
Understanding HIV stigma requires delving into the complex interplay of societal attitudes,
beliefs, and behaviors towards individuals living with or affected by HIV/AIDS. Stigma arises
from deep-seated fears, misconceptions, and moral judgments surrounding the virus, perpetuating
discrimination and marginalization. At its core, HIV stigma is rooted in the association of
HIV/AIDS with behaviors deemed socially unacceptable or morally reprehensible, such as drug
use, sex work, or homosexuality. These negative stereotypes fuel prejudice and discrimination,
leading to social rejection, ostracism, and even violence against individuals perceived to be living
with HIV. HIV stigma manifests in various forms, both overt and subtle, impacting all aspects of
an individual's life. People living with HIV often face discrimination in healthcare settings,
employment opportunities, and social interactions, leading to profound psychosocial and economic
consequences. Fear of stigma can deter individuals from seeking HIV testing, treatment, and
support services, contributing to delayed diagnosis, poor treatment adherence, and increased risk
of transmission. Moreover, HIV stigma intersects with other forms of discrimination, such as
sexism, homophobia, racism, and classism, exacerbating the vulnerabilities of marginalized
populations.40-61
The consequences of HIV stigma extend beyond individual experiences to affect entire
communities and societies. Stigma creates barriers to effective HIV prevention, care, and support
efforts, hindering progress in controlling the epidemic. It perpetuates silence and secrecy around
HIV/AIDS, impeding open dialogue and education about the virus. Furthermore, stigma
undermines efforts to address underlying social determinants of health, such as poverty, inequality,
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
and lack of access to healthcare, which contribute to the spread of HIV and its impact on vulnerable
populations. Understanding the drivers and consequences of HIV stigma is essential for developing
effective interventions and policies to address this pervasive issue. It requires challenging harmful
stereotypes, promoting accurate information about HIV transmission and prevention, and fostering
empathy and support for individuals living with or affected by HIV/AIDS. Moreover, combating
HIV stigma necessitates addressing broader structural inequalities and social injustices that
perpetuate discrimination and marginalization. By promoting inclusivity, respect, and dignity for
all individuals, regardless of their HIV status, we can work towards a future free from stigma and
discrimination, where everyone has the opportunity to live a healthy and fulfilling life.62-80
The Power of Collective Efforts
The power of collective efforts in confronting HIV stigma lies in the synergy of diverse
stakeholders coming together to challenge discriminatory attitudes and behaviors, promote
understanding, and drive positive change. Collective action brings together individuals,
communities, organizations, and institutions to leverage their collective resources, expertise, and
influence in addressing HIV stigma comprehensively. By fostering unity and solidarity, collective
efforts empower those affected by HIV/AIDS to advocate for their rights, access support services,
and challenge stigma at all levels of society. At the grassroots level, community-based
organizations and peer support networks play a pivotal role in mobilizing individuals and
providing a safe space for dialogue, education, and mutual support. These initiatives empower
people living with HIV to share their experiences, combat isolation and shame, and build
resilience. By fostering a sense of belonging and empowerment, community-based efforts
challenge the social isolation and discrimination often experienced by individuals affected by
HIV/AIDS, promoting self-esteem, well-being, and social inclusion.81-97
In addition to community-level initiatives, collective efforts at the national and international levels
are essential for driving policy change, promoting legal protections, and mobilizing resources to
combat HIV stigma. Advocacy campaigns, social movements, and alliances bring together diverse
stakeholders, including policymakers, healthcare professionals, activists, and civil society
organizations, to raise awareness, challenge discriminatory practices, and promote evidence-based
interventions. By amplifying the voices of those affected by HIV/AIDS, collective advocacy
efforts influence public opinion, shape policy agendas, and drive systemic reforms to address the
root causes of stigma and discrimination. Moreover, partnerships between government agencies,
non-governmental organizations, and private sector entities are instrumental in scaling up effective
interventions and leveraging resources to address HIV stigma comprehensively. Collaborative
initiatives facilitate knowledge sharing, capacity building, and innovation, enabling stakeholders
to learn from each other's experiences, adapt best practices to local contexts, and maximize the
impact of their efforts. By fostering collaboration and coordination across sectors, collective
efforts strengthen the overall response to HIV/AIDS and promote sustainable solutions to address
stigma and discrimination.98-105
Innovative Interventions and Best Practices
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
In the ongoing battle against HIV stigma, innovative interventions and best practices have emerged
to challenge stereotypes, promote empathy, and foster supportive environments for individuals
living with or affected by HIV/AIDS. These interventions leverage diverse approaches, from social
marketing campaigns to peer-led support groups, to address stigma comprehensively and promote
positive social change. By highlighting examples of innovative interventions and best practices,
we can glean insights into effective strategies for confronting HIV stigma and advancing public
health goals. One effective strategy is the use of social marketing campaigns and media advocacy
to challenge stereotypes and promote empathy towards individuals living with HIV/AIDS. These
campaigns utilize multimedia platforms, including television, radio, social media, and community
events, to disseminate accurate information about HIV/AIDS, challenge myths and
misconceptions, and promote messages of inclusion and acceptance. By engaging diverse
audiences and sparking conversations about HIV/AIDS, social marketing campaigns can shift
public attitudes and behaviors, reducing stigma and discrimination.106
Peer-led programs and support groups are another valuable intervention in addressing HIV stigma.
These initiatives provide safe spaces for individuals living with HIV to share their experiences,
receive emotional support, and access practical resources and information.107 Peer support
networks empower individuals to build resilience, develop coping strategies, and challenge stigma
in their communities. Moreover, peer-led interventions leverage the unique insights and
experiences of individuals living with HIV, fostering empathy and understanding among peers and
promoting solidarity within affected communities. Training programs for healthcare providers and
educators are also critical in addressing HIV stigma and promoting culturally competent care.
These programs equip healthcare professionals and educators with the knowledge, skills, and tools
to provide non-judgmental, sensitive care to individuals living with or affected by HIV/AIDS. By
raising awareness about HIV stigma and its impact on health outcomes, training programs
empower providers to challenge discriminatory practices, promote inclusive healthcare
environments, and support individuals in accessing testing, treatment, and support services.
Legal advocacy and policy reform efforts are essential in addressing structural barriers to HIV
prevention, care, and support.108 These initiatives aim to protect the rights of people living with
HIV, eliminate discriminatory laws and policies, and promote legal frameworks that uphold human
rights and dignity. By advocating for policy changes at the local, national, and international levels,
legal advocacy efforts can dismantle systemic barriers to HIV prevention, care, and support,
promoting access to essential services and challenging discrimination based on HIV status.
Innovative interventions and best practices in confronting HIV stigma demonstrate the
transformative potential of collective action in driving positive social change. By leveraging
diverse approaches, from social marketing campaigns to peer-led support groups, these
interventions challenge stereotypes, promote empathy, and foster supportive environments for
individuals living with or affected by HIV/AIDS. Moving forward, it is essential to scale up
successful interventions, adapt best practices to local contexts, and continue innovating new
strategies to address HIV stigma comprehensively and promote inclusive, equitable societies for
all.
Challenges and Opportunities
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
Addressing HIV stigma presents both challenges and opportunities in the global fight against the
epidemic. Understanding and navigating these complexities are essential for developing effective
strategies to confront stigma comprehensively and promote positive social change.
Challenges
HIV stigma is often deeply entrenched in cultural beliefs, norms, and values, making it challenging
to challenge and change.109 Misconceptions, fear, and moral judgments surrounding HIV/AIDS
continue to perpetuate stigma and discrimination in many communities, hindering efforts to
promote acceptance and support for individuals living with or affected by HIV/AIDS. HIV stigma
intersects with other forms of discrimination, including those based on gender, sexuality, race, and
socioeconomic status, exacerbating the vulnerabilities of marginalized populations. Structural
inequalities, such as poverty, lack of access to healthcare, and social exclusion, further marginalize
individuals living with HIV/AIDS, making it difficult to address stigma comprehensively. Limited
resources, including funding, trained personnel, and infrastructure, pose significant challenges to
addressing HIV stigma effectively. Many communities lack access to HIV education, testing,
treatment, and support services, perpetuating stigma and hindering efforts to promote early
diagnosis and linkage to care. The fear of disclosure and its potential consequences, including
social rejection, discrimination, and violence, can deter individuals from seeking testing,
treatment, and support services for HIV/AIDS. This fear of stigma often leads to delayed diagnosis,
poor treatment adherence, and increased risk of transmission, undermining efforts to control the
epidemic.
Opportunities
Community-based approaches empower individuals and communities to challenge HIV stigma
from within.110 By fostering dialogue, education, and mutual support, community-based initiatives
create safe spaces for individuals living with HIV to share their experiences, access resources, and
advocate for their rights. Advocacy campaigns and policy reform efforts play a crucial role in
challenging discriminatory laws and policies, promoting legal protections, and driving systemic
reforms to address HIV stigma. By amplifying the voices of those affected by HIV/AIDS,
advocacy efforts can influence public opinion, shape policy agendas, and promote inclusive legal
frameworks. Technological innovations, including social media platforms, mobile health apps, and
online support networks, offer new opportunities to reach diverse audiences and amplify advocacy
efforts. By leveraging technology, organizations can disseminate accurate information about
HIV/AIDS, challenge stereotypes, and promote empathy and support for individuals living with
or affected by HIV/AIDS. Education and awareness campaigns are essential for challenging myths
and misconceptions about HIV/AIDS, promoting understanding, and fostering empathy and
support for individuals living with or affected by HIV/AIDS. By raising awareness about HIV
stigma and its impact on health outcomes, education initiatives empower communities to challenge
stigma and discrimination and promote inclusive, supportive environments for all.
Conclusion
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
The battle against HIV stigma is multifaceted, requiring concerted efforts to address deep-seated
cultural beliefs, structural inequalities, and resource limitations while leveraging opportunities for
community engagement, advocacy, technological innovation, and education. Despite the
challenges posed by stigma, there are reasons for optimism as communities, organizations, and
individuals around the world continue to mobilize in the fight against HIV/AIDS. Through
collective action, we have seen the transformative power of unity in challenging stereotypes,
promoting empathy, and fostering supportive environments for individuals living with or affected
by HIV/AIDS. Grassroots initiatives, advocacy campaigns, and policy reforms have made
significant strides in raising awareness, challenging discriminatory practices, and promoting
inclusive legal frameworks. Moreover, technological innovations offer new opportunities to reach
diverse audiences and amplify advocacy efforts, while education and awareness campaigns
empower communities to challenge myths and misconceptions about HIV/AIDS and promote
understanding and support.
References
1. Pfeiffer EJ. Viral frictions: Global health and the persistence of HIV stigma in Kenya.
Rutgers University Press; 2022.
2. Quinn TC. Forty years of AIDS: a retrospective and the way forward. The Journal of
Clinical Investigation. 2021 Sep 15;131(18).
3. Obeagu EI, Obeagu GU, Odo EO, Igwe MC, Ugwu OP, Alum EU, Racheal P. Combatting
Stigma: Essential Steps in Halting HIV Spread. IAA Journal of Applied Sciences.
2024;11(1):22-29.
4. Odimegwu CO, Akinyemi JO, Alabi OO. HIV-stigma in Nigeria: review of research
studies, policies, and Programmes. AIDS research and treatment. 2017.
5. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed
Uninfected Children: A Review of African Perspective. Madonna University journal of
Medicine and Health Sciences. 2022;2(3):120-127.
6. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among
youths: A review of Africa perspective. Madonna University journal of Medicine and
Health Sciences. 2023;3(1):13-18.
https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
7. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS
Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023
;3(1):7-12.
https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
8. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer
screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023;
141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-
and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
9. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI.
Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in
Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
10. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics
management information system in HIV/AIDS comprehensive health facilities in Bayelsa
State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI:
10.22192/ijcrms.2017.03.01.004
11. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low
utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2):
1-5.DOI: 10.22192/ijcrms.2023.09.02.001
12. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub
Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-
survival-of-people-living-with-HIV-in-Nigeria.pdf.
13. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators
and barriers to retention in HIV care among HIV infected MSM attending Community
Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International.
2021;33(52B):10-19.
14. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC.
Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in
Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
15. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO.
TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice.
Journal of Pharmaceutical Research International. 2020;32(22):101-119.
16. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron
profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J
BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-
OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-
LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
17. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in
FMC owerri. International Journal of Current Microbiology and Applied Sciences.
2015;4(4):911-916.
https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeag
u__Getrude_Uzoma2.EMMA1.pdf.
18. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU,
Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS
victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res.
Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
19. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV
and TB co-infection among patients who used Directly Observed Treatment Short-course
centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-
Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
20. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary
Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna
University journal of Medicine and Health Sciences. 2022;2(3):110-119.
21. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu
HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA)
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban
Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.
links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-
MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-
SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-
NIGERIA.pdf.
22. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with
HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health
Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-
of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-
Enugu.pdf.
23. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial
thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res
Aca Rev. 2015; 3:139-144.
https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJC
RAR.pdf.
24. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices
o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH),
Nnewi. Ann Clin Lab Res. 2018;6(1):1-4.
links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-
Subjects-at-Nnamdi-Azikiwe.pdf
25. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of
prevention of mother to child transmission (PMTCT) of HIV on positivity rate in
Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI:
10.22192/ijcrms.2017.03.02.005
26. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in
Pakistan: Challenges and future recommendations at hand. Health Science Reports.
2023;6(8):e1450.
27. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection:
Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139.
links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-
infection-Bleeding.pdf.
28. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of
New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in
Developing Countries. Madonna University journal of Medicine and Health Sciences.
2022;2(3):128-134.
https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
29. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial
Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri
Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
30. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO.
Cascade variabilities in TB case finding among people living with HIV and the use of IPT:
assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical
Research International. 2020;32(24):9-18.
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
31. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on
demographic and risk factors among pregnant women attending clinics in Zaria Metropolis,
Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137.
links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-
based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-
Zaria-Metropolis-Nigeria.pdf.
32. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors
associated with non-adherence to antiretroviral therapy among people living with
HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI:
10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-
knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-
antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
33. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and
Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI:
10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-
HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
34. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of
malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci.
2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014
https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_pati
ents_coinfected_with_HIV.pdf
35. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC,
Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection
According to Demographic Factors among Pregnant Women Attending Clinics in Zaria
Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology.
2022;13(2):26-31.
36. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to
Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni
Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences.
2023;3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39.
37. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study
of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV,
Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun
Med. 2020;2(3):180-183.DOI: DOI: 10.32474/JCCM.2020.02.000137
links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-
Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-
HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
38. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI,
Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy
Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal,
Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International.
2021;33(47A):78-84.
39. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early
Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal
of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211.
http://research.sdpublishers.net/id/eprint/2819/.
40. Gwadz M, Leonard NR, Honig S, Freeman R, Kutnick A, Ritchie AS. Doing battle with
“the monster”: How high-risk heterosexuals experience and successfully manage HIV
stigma as a barrier to HIV testing. International journal for equity in health. 2018; 17:1-8.
41. Ullah AA, Huque AS, Ullah AA, Huque AS. Understanding and Exploring HIV/AIDS and
Discrimination. Asian Immigrants in North America with HIV/AIDS: Stigma,
Vulnerabilities and Human Rights. 2014:25-49.
42. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-
Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at
Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious
Diseases. 2022;10(4):1-7.
43. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to
Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of
Pharmaceutical Research International. 2021;33(57A):360-368.
44. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND
PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH
HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna
University journal of Medicine and Health Sciences. 2022;2(3):42-57.
https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
45. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human
Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University
journal of Medicine and Health Sciences. 2022;2(3):6-15.
https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
46. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu
EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A
PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO
STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
47. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO,
Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT
HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and
Pharmaceutical Sciences, 2015; 4(3): 153-160.
links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-
PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
48. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV
Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant
Biol. 2015;2(4):45-49.
49. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active
antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci.
2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004
links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-
highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
50. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human
Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI:
10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-
CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
51. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and
erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci.
2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-
haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
52. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC
Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910.
https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeag
u__Getrude_Uzoma.EMMA2.pdf.
53. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile
study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res.
Biol. Med. 2016;1(2):1-5.
54. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of
Religious Leaders. Newport International Journal of Research in Medical Sciences
(NIJRMS). 2023;3(2):28-31.
55. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review.
Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-67.
56. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular
diseases: The obnoxious Duos. Newport International Journal of Research in Medical
Sciences (NIJRMS). 2023;3(2):95-99.
57. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human
Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo
State University Teaching Hospital. International Journal of Medical Science and Dental
Research, 2018; 1 (2):08-14.
https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%
20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%2
0Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching
%20Hospital.pdf.
58. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some
haematological and biochemical parametrs in HIV patients before receiving treatment in
Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
59. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood
cell and differential count values in HIV positive patients receiving treatment in Federal
Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science,
Biotechnology and Pharama Research. 2014; 391:186-189.
60. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS
Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023;
3 (1): 7-12.
61. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV
Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
62. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma
MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins
C and E in HIV infected children in Umuahia, Abia state. International Journal of
Advanced Research in Biological Sciences. 2015;2(11):268-271.
63. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell
Anaemia. Newport International Journal of Scientific and Experimental Sciences
(NIJSES). 2023;3(2):56-59.
64. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin
resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci.
2018;4(2):104-108.
65. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral
infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
66. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne
Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal
Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
67. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV
and TB co-infection among patients who used Directly Observed Treatment Short-course
centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
68. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators
and barriers to retention in HIV care among HIV infected MSM attending Community
Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International.
2021;33(52B):10-19.
69. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS
knowledge into behavior change among secondary school adolescents in Uganda: A
review. Medicine (Baltimore). 2023;102(49): e36599. doi:
10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
70. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus
blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine
(Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID:
38013335; PMCID: PMC10681551.
71. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir
regimen against other regimens on some hematological parameters, CD4 count and viral
load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore).
2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID:
PMC10681510.
72. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human
immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46):
e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID:
PMC10659731.
73. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of
nutritional counseling and mental health services in HIV/AIDS management: A paradigm
shift. Medicine (Baltimore). 2023;102(41): e35673. doi: 10.1097/MD.0000000000035673.
PMID: 37832059; PMCID: PMC10578718.
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
74. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in
Pakistan: Challenges and future recommendations at hand. Health Sci Rep. 2023;6(8):
e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
75. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-
Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies
and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
76. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural
Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
77. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A
review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-
62.
78. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell
Anaemia. Newport International Journal of Scientific and Experimental Sciences
(NIJSES). 2023;3(2):56-9.
79. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection
Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa.
International Journal of Innovative and Applied Research. 2023;11(10):01-6.
80. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against
HIV. Elite Journal of Public Health. 2024;2(1):8-22.
81. Chaudoir SR, Fisher JD. Stigma and the “social epidemic” of HIV: understanding
bidirectional mechanisms of risk and resilience. InThe Oxford Handbook of Stigma,
Discrimination, and Health 2018 (p. 457). Oxford University Press.
82. Ferguson L, Gruskin S, Bolshakova M, Yagyu S, Fu N, Cabrera N, Rozelle M, Kasoka K,
Oraro‐Lawrence T, Stackpool‐Moore L, Motala A. Frameworks and measures for HIV‐
related internalized stigma, stigma and discrimination in healthcare and in laws and
policies: a systematic review. Journal of the International AIDS Society. 2022: e25915.
83. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients
through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
84. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for
monitoring and therapeutic strategies. Medicine. 2024;103(9):e37354.
85. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite
Journal of Immunology. 2024;2(1):1-3.
86. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite
Journal of Immunology. 2024;2(1):34-46.
87. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV:
A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
88. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection:
Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of
Medicine. 2024;2(1):35-46.
89. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and
Implications. Journal home page: http://www. journalijiar. com.;12(01).
90. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV:
Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
91. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-
infected with Malaria: A Comprehensive Review. Journal home page: http://www.
journalijiar. com.;12(01).
92. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children
Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
93. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV
Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV.
2024;2(1):1-5.
94. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria
Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
95. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for
Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
96. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on
HIV Patients. Sciences. 2024;4(1):38-44.
97. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T
Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science.
2024;2(1):33-42.
98. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on
Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive
Review. Elite Journal of Haematology. 2024;2(1):26-41.
99. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and
Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine.
2024;2(2):104-15.
100. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive
Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal
Health. Elite Journal of Immunology. 2024;2(1):47-64.
101. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in
Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-
7.
102. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to
Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
103. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria
Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
104. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-
Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-
31.
105. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker
for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page:
http://www. journalijiar. com.;12(01).
106. Andersson GZ, Reinius M, Eriksson LE, Svedhem V, Esfahani FM, Deuba K, Rao
D, Lyatuu GW, Giovenco D, Ekström AM. Stigma reduction interventions in people living
with HIV to improve health-related quality of life. The Lancet HIV. 2020;7(2): e129-140.
107. Reif S, Cooper H, Wilson E, Brown G, Beckwith N, Ward D. HIV stigma reduction
through peer-led advocacy training. AIDS Education and Prevention. 2021;33(4):303-311.
Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 22-36
https://epjournals.com/journals/EJPH
Citation: Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in
Confronting HIV Stigma. Elite Journal of Public Health, 2024; 2 (3): 22-36
108. Amon JJ, Kasambala T. Structural barriers and human rights related to HIV
prevention and treatment in Zimbabwe. InHealth Rights 2017: 371-388. Routledge.
109. Stangl AL, Earnshaw VA, Logie CH, Van Brakel W, C. Simbayi L, Barré I,
Dovidio JF. The Health Stigma and Discrimination Framework: a global, crosscutting
framework to inform research, intervention development, and policy on health-related
stigmas. BMC medicine. 2019; 17:1-3.
110. Kerrigan D, Kennedy CE, Morgan-Thomas R, Reza-Paul S, Mwangi P, Win KT,
McFall A, Fonner VA, Butler J. A community empowerment approach to the HIV response
among sex workers: effectiveness, challenges, and considerations for implementation and
scale-up. The Lancet. 2015;385(9963):172-185.
Article
Full-text available
Obesity, leukemia, and HIV/AIDS constitute a challenging clinical triad, each with distinct pathophysiological mechanisms and clinical implications. This paper reviews the intricate relationship between obesity and overall survival in leukemia patients living with HIV. Epidemiological trends reveal complex interactions among these conditions, with obesity linked to increased leukemia risk and HIV infection predisposing individuals to leukemia development. Mechanistically, obesity-induced inflammation, dysregulated adipokine secretion, and immune dysfunction may promote leukemogenesis and disease progression, exacerbated by HIV-related immunosuppression and systemic inflammation. Clinically, obesity poses challenges in risk stratification, treatment response, and supportive care, necessitating tailored interventions to optimize outcomes. Future research directions aim to elucidate underlying mechanisms and develop targeted therapeutic strategies. Understanding the impact of obesity on leukemia outcomes in HIV-positive individuals is critical for informing comprehensive patient care and advancing research efforts in this challenging clinical landscape.
Article
Full-text available
Body mass index (BMI) serves as a crucial indicator of nutritional status and metabolic health, yet its role in modulating immune function, particularly in leukemia patients living with HIV/AIDS, remains poorly understood. This paper explores the intricate relationship between BMI and immune function in this vulnerable population. Obesity, often characterized by elevated BMI, is associated with chronic low-grade inflammation and metabolic dysregulation, which can influence immune responses and disease outcomes. In the context of leukemia and HIV/AIDS, the interplay between BMI, immune function, and disease progression is complex and multifaceted. Understanding these interactions is essential for optimizing clinical management strategies and improving outcomes for leukemia patients with HIV/AIDS.
Article
Full-text available
Mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) remains a significant global health challenge, particularly in resource-limited settings. Despite remarkable progress in preventing MTCT through the implementation of comprehensive prevention of mother-to-child transmission (PMTCT) programs, gaps still exist, and transmission rates remain unacceptably high in certain regions. This review provides a comprehensive overview of the current landscape of MTCT prevention, highlighting key strategies, challenges, and future directions for reducing HIV transmission from mother to child. We discuss the importance of early HIV diagnosis and antiretroviral therapy (ART) initiation during pregnancy, options for infant prophylaxis, and the role of breastfeeding in MTCT. Additionally, we address the challenges associated with PMTCT program implementation, including access to care, retention in care, and stigma, and explore innovative approaches and emerging technologies for enhancing MTCT prevention efforts. By outlining a roadmap for reducing HIV transmission from mother to child, this review aims to guide policymakers, healthcare providers, and stakeholders in strengthening PMTCT programs and achieving the goal of eliminating pediatric HIV infections.
Article
Full-text available
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) coinfection pose significant challenges to global health, with intricate interactions between these pathogens influencing immune responses and disease outcomes. L-selectin, a cell adhesion molecule crucial for leukocyte trafficking and immune surveillance, has emerged as a key player in the pathogenesis of TB-HIV coinfection. This review explores the role of L-selectin in TB-HIV coinfection, focusing on its implications for immune activation and dysfunction. We discuss the modulation of L-selectin expression and function by TB and HIV, as well as its impact on immune responses, disease progression, and therapeutic strategies. Understanding the role of L-selectin in TB-HIV coinfection provides insights into disease pathogenesis and highlights opportunities for targeted interventions to improve patient outcomes.
Article
Full-text available
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) coinfection present a significant challenge to global health, with complex interactions between these pathogens influencing disease outcomes and treatment responses. L-selectin, a key mediator of leukocyte trafficking and immune activation, has emerged as a crucial molecule in the pathogenesis of TB-HIV coinfection. This review aims to elucidate the role of L-selectin in TB-HIV coinfection, focusing on its implications for immune activation and disease outcome. We discuss the intricate interplay between TB and HIV in modulating L-selectin expression and function, as well as its impact on immune responses, disease severity, and treatment outcomes. Furthermore, we explore the potential of targeting L-selectin-mediated immune pathways as a therapeutic strategy for improving disease control and patient prognosis in TB-HIV coinfection.
Article
Full-text available
The coexistence of obesity, leukemia, and HIV infection presents a multifaceted challenge in clinical management. This review aims to elucidate the intricate relationship between obesity and leukemia progression in individuals living with HIV. Obesity, characterized by chronic low-grade inflammation and metabolic dysregulation, influences leukemia progression through complex mechanisms involving adipose tissue dysfunction, altered immune responses, and systemic inflammation. Moreover, in HIV-positive individuals, the interplay between viral infection, immune dysfunction, and oncogenesis further exacerbates the impact of obesity on leukemia progression. Understanding these interactions is crucial for developing tailored therapeutic strategies to improve clinical outcomes in this vulnerable population.
Article
Full-text available
Deep venous thrombosis (DVT) is a significant complication observed in individuals living with Human Immunodeficiency Virus (HIV), contributing to morbidity and mortality. While the pathogenesis of DVT in HIV is multifactorial, recent research has implicated dysregulation of transcription factor GATA-1 in mediating thrombotic risk. GATA-1, traditionally recognized for its role in hematopoiesis, has emerged as a critical regulator of coagulation pathways, influencing platelet function, endothelial activation, and fibrinolysis. Understanding the molecular mechanisms underlying GATA-1-mediated coagulation dysregulation in HIV is essential for elucidating the pathogenesis of DVT and developing targeted therapeutic interventions. This review provides a comprehensive overview of the molecular mechanisms by which GATA-1 regulates coagulation pathways and its implications for the management of HIV-associated DVT. We discuss the interplay between GATA-1 and key components of the coagulation cascade, highlighting potential therapeutic strategies targeting GATA-1 to mitigate thrombotic risk in HIV.
Article
Full-text available
Preventing mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) is a critical component of maternal and child health programs worldwide. HIV-positive pregnant women face unique challenges and considerations in managing their health and preventing vertical transmission of HIV to their infants. This review provides recommendations for HIV-positive pregnant women, focusing on key strategies to promote optimal maternal and infant outcomes. Topics covered include the importance of early HIV diagnosis, initiation of antiretroviral therapy (ART), adherence to treatment regimens, infant feeding options, and access to healthcare services. By translating awareness into action, HIV-positive pregnant women can take proactive steps to protect their own health and prevent HIV transmission to their infants.
Article
Full-text available
Tuberculosis (TB) and human immunodeficiency virus (HIV) coinfection presents a complex challenge in global health, characterized by heightened disease severity and therapeutic complexities. Immune dysregulation plays a pivotal role in the pathogenesis of TB-HIV coinfection, influencing disease progression and clinical outcomes. L-selectin, a key adhesion molecule involved in immune cell trafficking, has emerged as a critical mediator in this interaction. Modulation of L-selectin expression impacts immune cell recruitment, homing, and activation, thereby influencing host immune responses to both TB and HIV. This review explores the modulation of L-selectin expression in TB-HIV coinfection and its implications for disease control. We discuss the mechanisms underlying L-selectin regulation, its role in immune cell trafficking, and the potential therapeutic strategies targeting L-selectin for disease management. Understanding the intricate interplay between L-selectin and TB-HIV coinfection offers promising avenues for the development of novel immunotherapeutic interventions and the optimization of disease control strategies.
Article
Full-text available
Tuberculosis (TB) and human immunodeficiency virus (HIV) coinfection represent a significant global health challenge, particularly in regions with high prevalence rates of both diseases. Despite advancements in understanding the individual pathogenesis of TB and HIV, the interplay between these pathogens in coinfection remains incompletely elucidated. Immune cell trafficking plays a crucial role in the host response to both TB and HIV infections, with L-selectin emerging as a key player in this process. This review explores the role of L-selectin in immune cell trafficking during TB-HIV coinfection and its implications for disease pathogenesis. Understanding the molecular mechanisms underlying L-selectin-mediated immune cell trafficking in the context of coinfection may uncover novel therapeutic targets for intervention and improve clinical outcomes for affected individuals.
Article
Full-text available
This review addresses the complex landscape of managing blood transfusions for individuals with HIV, uncovering challenges and considerations that influence patient care. As HIV has evolved into a manageable chronic condition with the advent of antiretroviral therapy (ART), the coexistence of transfusion requirements introduces a nuanced dynamic. Key challenges explored in this review encompass transfusion-related immunomodulation, the risk of alloimmunization, disparities in access to safe blood products, maintaining optimal adherence to ART, potential transfusion-related complications, pediatric considerations, and the ethical and psychosocial dimensions inherent in the intersection of blood transfusion and HIV management. Transfusion-related immunomodulation stands as a significant challenge, requiring careful monitoring due to its potential impact on the immune response of individuals with HIV. Alloimmunization, particularly in the context of multiple transfusions or prolonged exposure, poses a risk that necessitates strategic measures to minimize its occurrence. Disparities in access to safe blood products, especially in resource-limited settings, underscore the importance of establishing robust blood supply systems and advocating for equitable healthcare access for individuals with HIV. Maintaining optimal adherence to ART, a cornerstone in managing HIV, becomes challenging in the presence of potential drug interactions and alterations in absorption related to blood transfusions. The risk of transfusion-related complications, including infections and reactions, accentuates the need for stringent screening and monitoring protocols to ensure the safety of blood products. Pediatric considerations add an additional layer of complexity, demanding tailored approaches that account for developmental factors and the unique needs of younger populations with HIV.
Article
Full-text available
This review examines the intricate interplay between blood transfusion and antiretroviral medications, shedding light on the implications for patient care in individuals living with HIV. The coexistence of these two critical interventions introduces complexities that extend beyond routine considerations in both transfusion medicine and HIV management. Potential interactions between transfused blood components and antiretroviral drugs can impact drug efficacy, absorption, and metabolism, influencing treatment outcomes and posing challenges to healthcare providers. Immune system modulation, a phenomenon associated with blood transfusions, is explored in the context of its influence on the immunological effects of antiretroviral medications. Considerations extend to the pediatric population, where unique challenges arise concerning developmental aspects of drug metabolism and transfusion effects. Therapeutic drug monitoring (TDM) emerges as a valuable tool in managing the complex interactions between blood transfusion and antiretroviral medications. Regular monitoring of drug levels in the bloodstream allows for personalized adjustments to medication regimens, ensuring optimal therapeutic efficacy while minimizing the risk of toxicity. In conclusion, this review provides a comprehensive analysis of the interactions between blood transfusion and antiretroviral medications, offering insights into the challenges faced by healthcare providers and the considerations necessary for optimizing patient care. By enhancing our understanding of these interactions, healthcare professionals can tailor interventions, monitor treatment responses effectively, and provide individualized care for individuals living with HIV requiring blood transfusions.
Article
Full-text available
The ongoing battle against Human Immunodeficiency Virus (HIV) necessitates a comprehensive understanding of the intricate interplay between various components of the immune system. While the role of T lymphocytes has been extensively explored, recent research has illuminated the critical involvement of B lymphocytes and their dysfunction in the context of HIV/AIDS. This review delves into the implications of B lymphocyte dysfunction, dissecting its impact on humoral immunity, immunopathogenesis, vaccine development, and potential therapeutic interventions. In the realm of therapeutic interventions, this review evaluates current and potential strategies to rectify B lymphocyte dysfunction, ranging from immune modulatory therapies to targeted treatments aimed at restoring humoral immunity. The narrative concludes by outlining future perspectives, emphasizing the identification of biomarkers, advancements in vaccine design, and interdisciplinary collaboration as key areas of focus for further research.
Article
Full-text available
Human Immunodeficiency Virus (HIV) infection during pregnancy introduces a complex interplay between the maternal immune system and the imperative need for fetal development. This review delves into the nuanced relationship between maternal eosinophilic responses and HIV infection during pregnancy, offering insights into the immunological dynamics that influence both maternal and fetal outcomes. Eosinophils, traditionally associated with allergic responses, emerge as pivotal players in the adaptive immune responses of HIV-positive pregnant women. This abstract provides a succinct overview of the key themes explored in the review, emphasizing the implications of eosinophilic responses, potential roles in immune modulation, and the influence on vertical transmission risk. Further, it highlights the impact of antiretroviral therapy on maternal eosinophil dynamics, the delicate balance between immune tolerance and antiviral defenses, and the future perspectives and therapeutic implications that may optimize maternal-fetal health in the context of HIV.
Article
Full-text available
Human Immunodeficiency Virus (HIV) infection poses a continual challenge to global health, affecting the immune system and rendering individuals susceptible to opportunistic infections. With the advancements in Antiretroviral Therapy (ART), increasing attention is being directed towards holistic approaches, including nutritional interventions, to optimize immune health in people living with HIV. This review explores the intricate interplay between nutrition and immune health in the context of HIV. We examine the nutritional challenges faced by HIV patients, ranging from malabsorption to altered metabolism, and their implications for immune function. The review investigates the impact of micronutrients on immune parameters, evaluating the potential of supplementation to support immune health. Dietary patterns, including the Mediterranean and DASH diets, are scrutinized for their immunomodulatory effects in HIV-infected individuals. Furthermore, the review delves into the role of probiotics in maintaining gut health and supporting immune function in the HIV population. In conclusion, this review underscores the pivotal role of nutrition in enhancing immune health for individuals living with HIV, offering valuable insights for healthcare providers, researchers, and those navigating the complexities of HIV management.
Article
Full-text available
The complex interplay between CD8 T cells and Human Immunodeficiency Virus (HIV) infection is a pivotal determinant of disease progression and immune responses. This synoptic review provides an in-depth analysis of CD8 dynamics during HIV infection, elucidating key mechanisms, implications for disease progression, and potential therapeutic interventions. CD8 T cells play a central role in recognizing and eliminating HIV-infected cells, but sustained immune activation may lead to exhaustion, impacting their efficacy. This review synthesizes current knowledge on CD8 functionality, explores the delicate balance between immune activation and exhaustion, and assesses the dynamic changes in CD8 populations across different stages of HIV infection. Furthermore, it delves into the implications of CD8 dynamics for therapeutic interventions, evaluating existing strategies and highlighting emerging approaches. Despite significant progress, challenges persist in understanding the intricate nuances of CD8 responses to HIV. The review concludes by identifying gaps in knowledge and proposing future research directions. This comprehensive synthesis of CD8 dynamics in HIV infection serves as a valuable resource for researchers, clinicians, and policymakers striving to enhance our understanding of the immune responses crucial for combating HIV and developing effective therapeutic interventions.
Article
Full-text available
Human immunodeficiency virus (HIV) infection remains a significant global health concern, necessitating ongoing research and innovation in the quest for improved disease management. Traditional markers for monitoring HIV progression and the effectiveness of antiretroviral therapy have limitations in capturing the intricate immune responses and inflammatory dynamics in people with HIV. In recent years, the concept of inflammation ratios has gained prominence as a valuable tool for assessing and understanding the complex interplay between inflammation, immune function, and HIV. In this abstract, we provide an overview of the emerging field of utilizing inflammation ratios in the context of HIV and its implications for disease monitoring and therapeutic strategies. These ratios, such as the CD4/CD8 ratio, neutrophil-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio, offer a more comprehensive assessment of an individual's immune status and inflammatory state. By exploring the clinical implications of inflammation ratios, including their potential to predict disease complications and guide personalized treatment approaches, this publication sheds light on the potential benefits of incorporating inflammation ratios into routine HIV care. Furthermore, we emphasize the importance of ongoing research in this field to further refine our understanding of the utility and significance of inflammation ratios in improving the lives of people with HIV. Abbreviations: AIDS = acquired immunodeficiency syndrome, ART = antiretroviral therapy, CD4 = clusters of differentiation 4, CD8 = clusters of differentiation 8, HIV = human immunodeficiency virus, INRs = immunological non-responders, MLR = monocyte-to-lymphocyte ratio, NLR = neutrophil-to-lymphocyte ratio, PWH = people with HIV.
Article
Full-text available
This paper critically examines the complex interplay between maternal factors and infant immunological responses to Human Immunodeficiency Virus (HIV). The transmission of HIV from mother to child presents unique challenges that span the prenatal period, labor and delivery, and the postnatal phase, particularly during breastfeeding. Maternal influences, including the transfer of antibodies and immune factors through various avenues, significantly impact the early-life immune development of infants exposed to or infected with HIV. This paper explores the dynamics of vertical transmission, the delicate balance between breastfeeding benefits and HIV transmission risks, and the role of maternal antibodies in shaping infant immune resilience. The review also addresses the broader context of maternal health, encompassing nutritional status, co-infections, and antiretroviral therapy, as pivotal contributors to infant outcomes. Strategies to enhance infant immune resilience, such as antiretroviral therapy, maternal vaccination, and nutritional support, are discussed. The review concludes by outlining future research directions and identifying gaps in knowledge, underlining the importance of a multidisciplinary approach to unravel the complexities of maternal influence on infant immunological responses to HIV. This synthesis of current knowledge aims to inform research endeavors and guide the development of targeted interventions, ultimately improving outcomes for mother-infant pairs affected by HIV.
Article
Full-text available
Human Immunodeficiency Virus (HIV) poses a significant global health challenge, necessitating a deeper comprehension of the immune responses engaged in infection. B cell mediated immunity emerges as a pivotal aspect in the battle against HIV, with this review aiming to elucidate the intricacies of antibody responses, viral escape mechanisms, and their implications for vaccine development. Recent breakthroughs and therapeutic avenues are explored, alongside the persisting challenges that underscore the complexity of HIV immunology. This review consolidates current knowledge to provide a holistic understanding of B cell mediated immunity in HIV infection, offering insights that may shape future research endeavors and therapeutic strategies.
Article
Full-text available
Severe malaria remains a major global health concern, particularly in children under the age of 5. The co-occurrence of Human Immunodeficiency Virus (HIV) adds a layer of complexity to the clinical landscape, often necessitating blood transfusions as a critical intervention. This comprehensive review explores the synergistic effects of blood transfusion and HIV in the context of severe malaria in children under 5. We delve into the intricate interplay of these factors, examining their impact on anemia, immune modulation, and overall clinical outcomes. The review synthesizes current knowledge, addressing diagnostic challenges, treatment considerations, and the implications for pediatric care. Through an exploration of the synergistic effects, this article aims to provide insights that contribute to improved management strategies and enhanced outcomes for this vulnerable population.